Propanc Biopharma, Inc. (PPCB) Stock Score, Valuation & Financial Research

Propanc Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PPCB

Propanc Biopharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.37. These figures are a research snapshot, not a buy or sell recommendation.

What Propanc Biopharma, Inc. does

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Propanc Biopharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity and debt financing to fund the research, development, and clinical testing of its lead anti-cancer product candidate, PRP, until it can be commercialized or licensed to a partner.

Products and services

  • The company is developing PRP, a pro-enzyme therapy designed to treat advanced solid tumors by targeting cancer stem cells.

Brands and product families

  • PRP — Lead pro-enzyme therapeutic candidate for the treatment of solid tumors. Source

Customer types

Healthcare providers and patients with advanced solid tumors.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party CROs to conduct preclinical and clinical studies. Source

Business strengths to evaluate

  • Proprietary pro-enzyme therapy platform targeting cancer stem cells Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PPCB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.37
Market capitalization:
833.2K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.86M
Free cash flow:
USD -5.69M
Cash:
USD 832.01K
Total debt:
USD 509.12K
EPS:
USD -25.63

What stands out

  • Free cash flow is USD -5.69M, negative for the stored period.
  • The balance sheet shows USD 832.01K of cash versus USD 509.12K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 322.89K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PPCB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PPCB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PPCB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PPCB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PPCB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PPCB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.